Cyclin B1、P34cdc2在非小细胞肺癌中的表达及意义

目的为了研究非小细胞肺癌组织中Cyclin B1及P34cdc2的表达,探讨Cyclin B1及P34cdc2的表达与非小细胞肺癌临床病理特征的关系.方法随机收集非小细胞肺癌(含癌旁细支气管和/或小支气管增生组织和正常肺组织)标本100例.采用免疫组织化学SP法.结果显示在癌组织与癌旁细支气管和/或小支气管上皮增生组织及正常肺组织中Cyclin B1及P34cdc2表达差异有显著性(P＜0.01).在癌组织中有过表达;在癌旁细支气管和/或小支气管上皮增生组织中的表达较正常肺组织中的表达增强.100例非小细胞肺癌组织中Cyclin B1及P34cdc2表达呈正相关(P＜0.01),相关系数为0.966.癌旁细支气管和/或小支气管上皮增生组织中,Cyclin B1及P34cdc2的表达也呈正相关(P＜0.01),相关系数为0.638.组织类型、分化程度和淋巴结转移与Cyclin B1及P34cdc2的表达均无统计学意义(P＞0.05).不同临床分期的非小细胞肺癌,其Cyclin B1及P34 cdc2的表达差异有显著性(P＜0.05).结论 Cyclin B1及P34cdc2在非小细胞肺癌中有过表达现象,二者在M期前形成过多的促成熟因子(maturation promoting factor, MPF)从而加速非小细胞肺癌细胞跨越G2/M期关卡进入分裂期.过表达的Cyclin B1及P34cdc2可作为反映非小细胞肺癌细胞分裂增殖能力和临床分期的指标之一.

EXPRESSION AND SIGNIFICANCE OF CYCLIN B1 AND P34cdd2 IN HUMAN NON-SMALL CELL LUNG CANCER

Objective To study the expression of cyclin B 1 and P34 cdc2 in human non-small cell lung cancer (NSCLC), and the relationship between such expression and clinicopathologyical features of NSCLC.Method 100 NSCLC cases with neighboring noncancerous tissue and normal lung tissue were selected at random. These samples were detected by immunohistochemical methods. Result The expressions of cyclin B 1 and P34 cdc2 showed significant differences (P<0.01) between cancer tissues, neighboring noncancerous tissues with epithelial proliferating cells of bronchioles and small bronchi, and normal lung tissues.There was overexpression of cyclin B 1 and P34 cdc2 in NSCLC. The expressions of cyclin B 1 and P34 cdc2 in neighboring noncancerous tissues were stronger than those in normal lung tissues. Significant positive correlation was found between the expression of cyclin B 1 and P34 cdc2 in 100 NSCLC cases (P<0.01), the correlation coefficient being 0.966. The positive correlation was also found between the expression of cyclin B 1 and P34 cdc2 in neighboring noncancerous tissues (P<0.01), and the correlation coefficient was 0.638. No statistical significance was found betwwen the different histological types, the differentiated degree, lymphatic metastasis and the expressions of cyclin B 1 and P34 cdc2 (P>0.05). Statistical significance was marked between different clinical stages of NSCLC and expressions of cyclin B 1 and P34 cdc2 (P<0.05). Conclusion The overexpression of cyclin B 1 and P34 cdc2 in NSCLC suggests that, before M phase, such overexpression form more MPF to make NSCLC cells overcome G 2/M checkpoint and enter M phase. The overexpression of cyclin B 1 and P34 cdc2 may be used as a mark in showing the dividing and proliferating ability of NSCLC and determining the clinical stage of NSCLC.;